<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7822065\results\search\disease\results.xml">
  <result pre="and HDAC6 were 13.9, 12.1, and 7.71â€‰nM, respectively. In the" exact="cancer" post="cell based screening, molecule I13 showed increased antiproliferative activities"/>
  <result pre="inhibitors (HDACIs) have been widely investigated in the treatment of" exact="cancer" post="and other diseases21. HDAC inhibitors have been extensively studied"/>
  <result pre="Drug Administration (FDA) for the treatment of refractory cutaneous T-cell" exact="lymphoma" post="(CTCL). PDX10124 and LBH58925 have been approved for the"/>
  <result pre="LBH58925 have been approved for the treatment of peripheral T-cell" exact="lymphoma" post="(PTCL) and multiple myeloma, respectively. Chidamide26 is a benzamide"/>
  <result pre="approved for the treatment of peripheral T-cell lymphoma (PTCL) and" exact="multiple myeloma," post="respectively. Chidamide26 is a benzamide HDACI approved by Chinese"/>
  <result pre="derived molecules were evaluated in the enzymatic assay, inÂ vitro" exact="cancer" post="cell based screening, apoptosis, and inÂ vivo anticancer test."/>
  <result pre="assay, also showed high inÂ vitro antiproliferative activity in the" exact="cancer" post="cell based test. The IC50 values of compound I3"/>
  <result pre="SAHA (0.88â€‰Î¼M). A series of tumour cell lines including the" exact="lung cancer" post="A549, Calu-3, SPC-A-1, H322, H1299, breast cancer MDA-MB-231, MCF-7,"/>
  <result pre="(0.88â€‰Î¼M). A series of tumour cell lines including the lung" exact="cancer" post="A549, Calu-3, SPC-A-1, H322, H1299, breast cancer MDA-MB-231, MCF-7,"/>
  <result pre="lines including the lung cancer A549, Calu-3, SPC-A-1, H322, H1299," exact="breast cancer" post="MDA-MB-231, MCF-7, MDA-MB-468, colon carcinoma LoVo, Colo205, ovarian cancer"/>
  <result pre="including the lung cancer A549, Calu-3, SPC-A-1, H322, H1299, breast" exact="cancer" post="MDA-MB-231, MCF-7, MDA-MB-468, colon carcinoma LoVo, Colo205, ovarian cancer"/>
  <result pre="H1299, breast cancer MDA-MB-231, MCF-7, MDA-MB-468, colon carcinoma LoVo, Colo205," exact="ovarian cancer" post="A2780, SKOV3, gastric cancer MKN45, pancreatic cancer PNAC-1, leukemic"/>
  <result pre="breast cancer MDA-MB-231, MCF-7, MDA-MB-468, colon carcinoma LoVo, Colo205, ovarian" exact="cancer" post="A2780, SKOV3, gastric cancer MKN45, pancreatic cancer PNAC-1, leukemic"/>
  <result pre="MDA-MB-468, colon carcinoma LoVo, Colo205, ovarian cancer A2780, SKOV3, gastric" exact="cancer" post="MKN45, pancreatic cancer PNAC-1, leukemic K562, and multiple myeloma"/>
  <result pre="carcinoma LoVo, Colo205, ovarian cancer A2780, SKOV3, gastric cancer MKN45," exact="pancreatic cancer" post="PNAC-1, leukemic K562, and multiple myeloma OPM2 cells were"/>
  <result pre="LoVo, Colo205, ovarian cancer A2780, SKOV3, gastric cancer MKN45, pancreatic" exact="cancer" post="PNAC-1, leukemic K562, and multiple myeloma OPM2 cells were"/>
  <result pre="SKOV3, gastric cancer MKN45, pancreatic cancer PNAC-1, leukemic K562, and" exact="multiple myeloma" post="OPM2 cells were cultured for the antiproliferative assay of"/>
  <result pre="(IC50, Î¼Ma). Cell line Tumour type I13 SAHA A549 Lung" exact="cancer" post="3.15 1.73 Calu-3 Lung cancer 1.26 3.18 SPC-A-1 Lung"/>
  <result pre="type I13 SAHA A549 Lung cancer 3.15 1.73 Calu-3 Lung" exact="cancer" post="1.26 3.18 SPC-A-1 Lung cancer 0.81 1.11 H322 Lung"/>
  <result pre="cancer 3.15 1.73 Calu-3 Lung cancer 1.26 3.18 SPC-A-1 Lung" exact="cancer" post="0.81 1.11 H322 Lung cancer 14.90 73.97 H1299 Lung"/>
  <result pre="cancer 1.26 3.18 SPC-A-1 Lung cancer 0.81 1.11 H322 Lung" exact="cancer" post="14.90 73.97 H1299 Lung cancer 7.67 4.57 MDA-MB-231 Breast"/>
  <result pre="cancer 0.81 1.11 H322 Lung cancer 14.90 73.97 H1299 Lung" exact="cancer" post="7.67 4.57 MDA-MB-231 Breast carcinoma 0.78 1.11 MCF-7 Breast"/>
  <result pre="carcinoma 2.19 1.07 Colo205 Colon carcinoma 2.42 2.01 A2780 Ovarian" exact="cancer" post="4.60 27.3 SKOV3 Ovarian cancer 1.44 1.73 MKN45 Gastric"/>
  <result pre="carcinoma 2.42 2.01 A2780 Ovarian cancer 4.60 27.3 SKOV3 Ovarian" exact="cancer" post="1.44 1.73 MKN45 Gastric cancer 18.19 16.06 PNAC-1 Pancreatic"/>
  <result pre="cancer 4.60 27.3 SKOV3 Ovarian cancer 1.44 1.73 MKN45 Gastric" exact="cancer" post="18.19 16.06 PNAC-1 Pancreatic cancer 1.17 6.57 K562 Leukemia"/>
  <result pre="cancer 1.44 1.73 MKN45 Gastric cancer 18.19 16.06 PNAC-1 Pancreatic" exact="cancer" post="1.17 6.57 K562 Leukemia 2.87 4.32 OPM2 Multiple myeloma"/>
  <result pre="4ZhangL, HanYT, JiangQX, et al.Trend of histone deacetylase inhibitors in" exact="cancer" post="therapy: isoform selectivity or multitargeted strategy. Med Res Rev2015;35:63â€&quot;84.24782318"/>
  <result pre="glucocorticoid receptor. Mol Cell2005;18:601â€&quot;7.15916966 11PatelMM, PatelBM.Repurposing of sodium valproate in" exact="colon cancer" post="associated with diabetes mellitus: role of HDAC inhibition. Eur"/>
  <result pre="receptor. Mol Cell2005;18:601â€&quot;7.15916966 11PatelMM, PatelBM.Repurposing of sodium valproate in colon" exact="cancer" post="associated with diabetes mellitus: role of HDAC inhibition. Eur"/>
  <result pre="belinostat. Synth Commun2010;40:2520â€&quot;4. 25NeriP, BahlisNJ, LonialSPanobinostat for the treatment of" exact="multiple myeloma." post="Expert Opin Investig Drugs2012;21:733â€&quot;47. 26DongM, NingZ, NewmanMJ, et al.Phase"/>
  <result pre="allosteric hydrazide-containing class I histone deacetylase inhibitors for use in" exact="acute myeloid leukemia." post="J Med Chem2016;59:9942â€&quot;59.27754681"/>
  <result pre="hydrazide-containing class I histone deacetylase inhibitors for use in acute" exact="myeloid leukemia." post="J Med Chem2016;59:9942â€&quot;59.27754681"/>
 </snippets>
</snippetsTree>
